Back to Blogs
  • Publish Date: Posted 2 months ago
  • Author: Steve Twinley

​Cell & Gene Therapy is widely accepted as the fastest-growing area within the Pharmaceutical industry in the UK.

 

The latest Skills Report, published by Cell & Gene Therapy Catapult at the end of 2021, shows that the UK industry is already the size that had been predicted for 2024. It is reflected in the number of mergers and acquisitions that have taken place in the last 12 months, involving major companies such as Novartis, Sanofi and Takeda.

 

How has the UK been able to advance so quickly within this field, with a predicted value of £10 billion for the UK ATMP sector by 2035?

 

The existence of the Cell & Gene Therapy Catapult certainly helps, providing businesses with a platform to advance from research into full-scale commercialisation.

 

Similarly, the new Life Sciences Innovative Manufacturing Fund (LSIMF) will help to advance a number of Advanced Therapy projects, by providing £60 million for life science projects.

 

There are also a number of initiatives, such as the Innovative Licensing and Access Pathway (ILAP), to remove legislative ‘red tape’, accelerate the availability of medicines direct to patients and streamline the provision of regulatory advice to both large and small businesses.

 

It is exciting to work in such an innovative sector, where there is a clear shared ambition to develop pioneering new treatments that will make such a huge impact on people’s lives.

 For further information and insights, visit this page for a comprehensive look at recent and upcoming developments in the Advanced Therapy sector in the UK: click here